Skip to main content
. Author manuscript; available in PMC: 2014 Jul 1.
Published in final edited form as: Biochim Biophys Acta. 2012 Aug 16;1830(7):3987–4003. doi: 10.1016/j.bbagen.2012.08.005

Figure 9.

Figure 9

In-vivo and in-vitro studies in subjects with SBP2 deficiency. (A) In-vivo studies: Serum TSH and corresponding serum T4 and T3 levels, before and during the oral administration of incremental doses of L-T4 and L-T3. Note the higher concentrations of T4 required to reduce serum TSH in the affected subjects; (B) In-vitro studies of deiodinase 2 in cultured skin fbroblasts: Baseline and stimulated D2 activity is significantly lower in affected individuals. There is significant increase of DIO2 mRNA with dibutyryl cyclic adenosine monophosphate [(db)-cAMP), in both unaffected and affected (*p <0.001) while there are no significant differences in baseline (db)-cAMP stimulated DIO2 mRNA in affected versus the unaffected. (Modified from Refetoff S, Dumitrescu AM. Syndromes of reduced sensitivity to thyroid hormone: genetic defects in hormone receptors, cell transporters and deiodination. Best Pract Res Clin Endocrinol Metab. 2007 Jun;21(2):277–305.)